<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234114</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT03234114</nct_id>
  </id_info>
  <brief_title>Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)</brief_title>
  <official_title>Optimal Antithrombotic Therapy for Acute Coronary Syndrome Patients Concomitant With Atrial Fibrillation and Implanted With New-generation Drug-eluting Stent: OPTImal Management of Antithrombotic Agents (OPTIMA-3, 4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with&#xD;
      acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and&#xD;
      undergoing new generation drug eluting stent (DES) implantation at 70 centers nationwide in&#xD;
      China and contains two sub-studies.&#xD;
&#xD;
      In the OPTIMA-3 sub-study, 2274 subjects who choose warfarin as anticoagulant will randomly&#xD;
      receive triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg&#xD;
      od and aspirin 100 mg od) for 1 month or 6 months in a 1:1 ratio then quit aspirin till 12&#xD;
      months after percutaneous coronary intervention (PCI). The primary endpoint of the OPTIMAL-3&#xD;
      is a composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic&#xD;
      thromboembolism and unplanned revascularization up to 12 months; the major secondary endpoint&#xD;
      is the International Society of Thrombosis and Hemostasis (ISTH) major bleeding or clinically&#xD;
      relevant non-major bleeding (CRNMB).&#xD;
&#xD;
      In the OPTIMA-4 sub-study, 1472 subjects who prefer dabigatran will be randomly assigned in a&#xD;
      1:1 ratio to a dual antithrombotic therapy of dabigatran 110 mg twice daily with ticagrelor&#xD;
      90 mg twice daily or with clopidogrel 75 mg od for 12 months after PCI. The primary safety&#xD;
      endpoint of the OPTIMAL-4 is ISTH major bleeding or CRNMB at 12 months; the primary efficacy&#xD;
      endpoint is a composite of cardiovascular death, myocardial infarction, ischemic stroke,&#xD;
      systemic thromboembolism and unplanned revascularization.&#xD;
&#xD;
      Other secondary endpoints comprise death (cardiovascular, non- cardiovascular), MI (fatal or&#xD;
      non-fatal, Q-wave or non-Q-wave), unplanned revascularization (target or non-target vessel,&#xD;
      target or non-target lesion), stent thrombosis (possible, probable, definite), stroke&#xD;
      (hemorrhage or ischemic), all bleeding (ISTH and BARC criteria) and net adverse events.&#xD;
&#xD;
      All endpoints will be collected and compared between subgroups and sub-studies during&#xD;
      hospitalization and in 1 month (± 7 days), 6 months (± 7 days) and 12 months (± 7 days) for&#xD;
      office visits and in 2 weeks (± 7 days), 2 months (± 7 days) and 3 months (± 7 days) for&#xD;
      phone call visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint of OPTIMA-3</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic thromboembolism and unplanned revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint of OPTIMA-4</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>ISTH major bleeding or CRNMB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint of OPTIMA-4</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic thromboembolism and unplanned revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major secondary endpoint of OPTIMA-3</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>Major bleeding or clinically relevant non-major bleeding assessed by the ISTH definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary endpoints of OPTIMA-3/4</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>Death (cardiovascular, non- cardiovascular), MI (fatal or non-fatal, Q-wave or non-Q-wave), unplanned revascularization (target or non-target vessel, target or non-target lesion), stent thrombosis (possible, probable, definite), stroke (hemorrhage or ischemic), all bleeding (ISTH and BARC criteria) and net adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3746</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <condition>Non-valvular Atrial Fibrillation (NVAF)</condition>
  <arm_group>
    <arm_group_label>1-month TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month (30 days) then quit aspirin till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-month TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 6 months (180 days）then quit aspirin till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DT-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg qd for 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DT-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple antithrombotic therapy</intervention_name>
    <description>Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg per day (Bayer, Germany) and clopidogrel 75 mg per day (Sanofi, France)</description>
    <arm_group_label>1-month TT</arm_group_label>
    <arm_group_label>6-month TT</arm_group_label>
    <other_name>TT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antithrombotc therapy</intervention_name>
    <description>Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain) or clopidogrel 75 mg per day (Sanofi, France)</description>
    <arm_group_label>12-month DT-1</arm_group_label>
    <arm_group_label>12-month DT-2</arm_group_label>
    <other_name>DT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years;&#xD;
&#xD;
          -  ACS patients concomitant non-valvular AF (paroxysmal, persistent and permanent)&#xD;
             underwent PCI and new-generation DES implantation;&#xD;
&#xD;
          -  CHA2DS2-VASc score ≥ 2;&#xD;
&#xD;
          -  Acceptable risk of bleeding at the discretion of the researchers (e.g. HAS-BLED score&#xD;
             ≤ 2)&#xD;
&#xD;
          -  Consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  DES implanted in the left main coronary artery&#xD;
&#xD;
          -  Cardiogenic shock or Killip III-IV&#xD;
&#xD;
          -  STEMI patients with malignant arrhythmias or underwent electrodefibrillation or CPR or&#xD;
             with cardiac mechanical complications (heart rupture, ventricular septal perforation,&#xD;
             nipple muscle fracture, etc.)&#xD;
&#xD;
          -  History of gastrointestinal or intracranial hemorrhage; active bleeding, trauma or&#xD;
             major surgery within one month; suspected or diagnosed aortic dissection&#xD;
&#xD;
          -  Ischemic stroke with limb dysfunction or dysphasia&#xD;
&#xD;
          -  Known allergy or intolerance to the study medications: warfarin, clopidogrel, aspirin,&#xD;
             dabigatran, ticagrelor and heparin&#xD;
&#xD;
          -  Participating in other ongoing trials&#xD;
&#xD;
          -  Planned surgery in 12 months requiring to withdraw the antiplatelet agents&#xD;
&#xD;
          -  Planned RFCA or left atrial appendage occlusion in the next 12m&#xD;
&#xD;
          -  Abnormal liver or kidney function (ALT ≥ 3 ULN; estimated CrCl &lt; 30 ml/min calculated&#xD;
             by Cockcroft-Gault equation); diagnosed liver cirrhosis&#xD;
&#xD;
          -  Hematological disease with bleeding tendency; hemoglobin &lt; 100 g/L, platelet count &lt;&#xD;
             100 × 10^9 /L&#xD;
&#xD;
          -  Malignancies or life expectancy less than 1 year&#xD;
&#xD;
          -  Pregnant (present, suspected, or planned) or lactating woman&#xD;
&#xD;
          -  Patients who are taking drugs which may interact with study agents, such as&#xD;
             miconazole, ketoconazole, fluconazole, voriconazole, itraconazole, posaconazole,&#xD;
             efinaconazole, and rifampicin, etc.&#xD;
&#xD;
          -  Patients with any other conditions that may not be suitable to participate in the&#xD;
             trial at the discretion of the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <phone>+86-13701465229</phone>
    <email>drcjli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoxuan Gong, MD</last_name>
    <phone>+86-18851727059</phone>
    <email>xiaoxuangong@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chunjian Li, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxuan Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>new generation drug eluting stent (DES)</keyword>
  <keyword>antithrombotic therapy</keyword>
  <keyword>randomized clinical trial (RCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

